Literature DB >> 17205601

Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model.

Paweena Kreunin1, Chul Yoo, Virginia Urquidi, David M Lubman, Steve Goodison.   

Abstract

A combination of LC and MS was applied to an isogenic breast tumor metastasis model to identify proteins associated with a cellular phenotype. Chromatofocusing followed by nonporous-RP-HPLC/ESI-TOF MS was applied to cell lysates of a pair of monoclonal cell lines from the human breast carcinoma cell line MDA-MB-435 that have different metastatic phenotypes in immune-compromised mice. This method was developed to separate proteins based on pI and hydrophobicity. The high resolution and mass accuracy of ESI-TOF measurements provided a good correlation of theoretical MW and experimental Mr values of intact proteins measured in mass maps obtained in the pH range 3.8-6.4. The isolated proteins were digested by trypsin and analyzed by MALDI-TOF MS, MALDI-QIT-TOF MS, and monolith-based HPLC/MS/MS. The unique combination of the techniques provided valuable information including quantitation and modification of proteins. We identified 89 selected proteins, of which 43 were confirmed as differentially expressed. Metastasis-associated proteins included galectin-1, whereas annexin I and annexin II were associated with the nonmetastatic phenotype. In this study, we demonstrate that combining a variety of MS tools with a multidimensional liquid-phase separation provides the ability to map cellular protein content, to search for modified proteins, and to correlate protein expression with cellular phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17205601      PMCID: PMC2663396          DOI: 10.1002/pmic.200600272

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  50 in total

1.  A comparison of drug-treated and untreated HCT-116 human colon adenocarcinoma cells using a 2-D liquid separation mapping method based upon chromatofocusing PI fractionation.

Authors:  Fang Yan; Balanehru Subramanian; Alexander Nakeff; Timothy J Barder; Steven J Parus; David M Lubman
Journal:  Anal Chem       Date:  2003-05-15       Impact factor: 6.986

2.  What to do with "one-hit wonders"?

Authors:  Timothy D Veenstra; Thomas P Conrads; Haleem J Issaq
Journal:  Electrophoresis       Date:  2004-05       Impact factor: 3.535

3.  A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification.

Authors:  Rick L Hamler; Kan Zhu; Nathan S Buchanan; Paweena Kreunin; Maureen T Kachman; Fred R Miller; David M Lubman
Journal:  Proteomics       Date:  2004-03       Impact factor: 3.984

4.  From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis.

Authors:  Shi-Jian Ding; Yan Li; Ye-Xiong Tan; Man-Rong Jiang; Bo Tian; Ying-Kun Liu; Xiao-Xia Shao; Sheng-Long Ye; Jia-Rui Wu; Rong Zeng; Hong-Yang Wang; Zhao-You Tang; Qi-Chang Xia
Journal:  Mol Cell Proteomics       Date:  2003-10-30       Impact factor: 5.911

Review 5.  Basic and translational advances in cancer metastasis: Nm23.

Authors:  Taoufik Ouatas; Massimiliano Salerno; Diane Palmieri; Patricia S Steeg
Journal:  J Bioenerg Biomembr       Date:  2003-02       Impact factor: 2.945

6.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy.

Authors:  Phil Oh; Yan Li; Jingyi Yu; Eberhard Durr; Karolina M Krasinska; Lucy A Carver; Jacqueline E Testa; Jan E Schnitzer
Journal:  Nature       Date:  2004-06-10       Impact factor: 49.962

7.  Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein.

Authors:  Steve Goodison; Kanji Kawai; Jun Hihara; Ping Jiang; Meng Yang; Virginia Urquidi; Robert M Hoffman; David Tarin
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

Review 8.  Annexin 1: more than an anti-phospholipase protein.

Authors:  Luca Parente; Egle Solito
Journal:  Inflamm Res       Date:  2004-03-18       Impact factor: 4.575

9.  Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status.

Authors:  Juana Maria Garcia Pedrero; M Pilar Fernandez; Reginald O Morgan; Agustin Herrero Zapatero; Maria Victoria Gonzalez; Carlos Suarez Nieto; Juan Pablo Rodrigo
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  Detection of differentially expressed genes in an isogenic breast metastasis model using RNA arbitrarily primed-polymerase chain reaction coupled with array hybridization (RAP-array).

Authors:  Derek D Sloan; Ben Nicholson; Virginia Urquidi; Steve Goodison
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

View more
  10 in total

1.  Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry.

Authors:  Paweena Kreunin; Chul Yoo; Virginia Urquidi; David M Lubman; Steve Goodison
Journal:  Cancer Genomics Proteomics       Date:  2007 Sep-Oct       Impact factor: 4.069

2.  An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis.

Authors:  Piia-Riitta Karhemo; Suvi Ravela; Marko Laakso; Ilja Ritamo; Olga Tatti; Selina Mäkinen; Steve Goodison; Ulf-Håkan Stenman; Erkki Hölttä; Sampsa Hautaniemi; Leena Valmu; Kaisa Lehti; Pirjo Laakkonen
Journal:  J Proteomics       Date:  2012-07-17       Impact factor: 4.044

3.  Nuclear repartitioning of galectin-1 by an extracellular glycan switch regulates mammary morphogenesis.

Authors:  Ramray Bhat; Brian Belardi; Hidetoshi Mori; Peiwen Kuo; Andrew Tam; William C Hines; Quynh-Thu Le; Carolyn R Bertozzi; Mina J Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-05       Impact factor: 11.205

4.  NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer.

Authors:  Rikke R Lund; Rikke Leth-Larsen; Tina Di Caterino; Mikkel G Terp; Jeanette Nissen; Anne-Vibeke Lænkholm; Ole N Jensen; Henrik J Ditzel
Journal:  Mol Cell Proteomics       Date:  2015-09-08       Impact factor: 5.911

Review 5.  Breast tumor metastasis: analysis via proteomic profiling.

Authors:  Steve Goodison; Virginia Urquidi
Journal:  Expert Rev Proteomics       Date:  2008-06       Impact factor: 3.940

6.  Differential protein expression analysis using stable isotope labeling and PQD linear ion trap MS technology.

Authors:  Jenny M Armenta; Ina Hoeschele; Iulia M Lazar
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-04       Impact factor: 3.109

7.  Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling.

Authors:  Paweena Kreunin; Jia Zhao; Charles Rosser; Virginia Urquidi; David M Lubman; Steve Goodison
Journal:  J Proteome Res       Date:  2007-05-23       Impact factor: 4.466

8.  miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations.

Authors:  Karina G Thomsen; Mikkel G Terp; Rikke R Lund; Rolf Søkilde; Daniel Elias; Martin Bak; Thomas Litman; Hans C Beck; Maria B Lyng; Henrik J Ditzel
Journal:  Oncotarget       Date:  2015-10-06

9.  Do serum biomarkers really measure breast cancer?

Authors:  Jonathan L Jesneck; Sayan Mukherjee; Zoya Yurkovetsky; Merlise Clyde; Jeffrey R Marks; Anna E Lokshin; Joseph Y Lo
Journal:  BMC Cancer       Date:  2009-05-28       Impact factor: 4.430

10.  Nuclear galectin-1-FOXP3 interaction dampens the tumor-suppressive properties of FOXP3 in breast cancer.

Authors:  Yuan Gao; Xiaoju Li; Zhen Shu; Kuo Zhang; Xiaochang Xue; Weina Li; Qiang Hao; Zhaowei Wang; Wangqian Zhang; Shuning Wang; Cheng Zeng; Dong Fan; Wei Zhang; Yingqi Zhang; Huadong Zhao; Meng Li; Cun Zhang
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.